Stockscreener 앱 받기
0.5144
2.25%
-0.0153
전일 마감가:
$0.5297
열려 있는:
$0.53
하루 거래량:
439.59K
Relative Volume:
1.10
시가총액:
$3.23M
수익:
$5.66M
순이익/손실:
$-15.88M
주가수익비율:
-0.0455
EPS:
-11.3134
순현금흐름:
$-10.93M
1주 성능:
-17.47%
1개월 성능:
-37.61%
6개월 성능:
-39.17%
1년 성능:
-93.83%
1일 변동 폭
$0.507
$0.5305
1주일 범위
$0.507
$0.62
52주 변동 폭
$0.507
$13.50
Bioaffinity Technologies Inc Stock (BIAF) Company Profile
명칭
Bioaffinity Technologies Inc
전화
210-698-5334
주소
3300 NACOGDOCHES ROAD, SAN ANTONIO
Compare BIAF vs TMO, DHR, IDXX, NTRA, A
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BIAF
Bioaffinity Technologies Inc
|
0.5144 | 4.28M | 5.66M | -15.88M | -10.93M | -11.31 |
TMO
Thermo Fisher Scientific Inc
|
587.31 | 207.93B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
203.68 | 138.14B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
588.06 | 43.87B | 4.45B | 1.10B | 1.06B | 13.59 |
NTRA
Natera Inc
|
318.30 | 36.95B | 2.50B | -226.32M | 71.51M | -1.6412 |
A
Agilent Technologies Inc
|
145.14 | 38.94B | 7.23B | 1.41B | 1.09B | 4.979 |
Bioaffinity Technologies Inc 주식(BIAF)의 최신 뉴스
bioAffinity Technologies Inc (BIAF) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
bioAffinity Technologies Publishes New Clinical Framework Addressing Growing Market for Pulmonary Nodule Risk Stratification and Early Lung Cancer Detection Using CyPath® Lung - BioSpace
bioAffinity Technologies Inc (BIAF) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
bioAffinity Technologies Inc (BIAF) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
bioAffinity, Pictor Collaborate on Asthma and COPD Tests - respiratory-therapy.com
bioAffinity Technologies Highlights CyPath Lung Clinical Framework - TipRanks
bioAffinity Technologies publishes clinical framework to integrate CyPath® Lung into nodule evaluation - TradingView
bioAffinity Technologies, Inc. Revenue Breakdown – BOATS:BIAFW - TradingView
bioAffinity Technologies, Inc. Revenue Breakdown – BOATS:BIAF - TradingView
TradingKey - TradingKey
bioAffinity Technologies, Inc. (BIAF) stock price, news, quote and history - Yahoo Finance UK
Top QumulusAI (QMLS) Competitors 2026 - MarketBeat
bioAffinity Technologies and Pictor®, Inc. Partner to Develop and Commercialize bioAffinity's Diagnostics for Asthma and COPD | Newswise - Newswise
bioAffinity Technologies Inc (BIAF) Income Statement - TradingKey
bioAffinity Technologies Inc (BIAF) Cash Flow - TradingKey
bioAffinity Technologies Inc (BIAF) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
BIAF Stock Gains As CyPath Sales Surge 146% In Q1 - Stocktwits
BIAF|bioAffinity Technologies Inc|Price:0.663|Chg%:-0.005 - TradingKey
bioAffinity Technologies Inc (BIAF) Valuation: PE, PB & Fair Value Analysis - TradingKey
BIAF vs. BDSX: Which Cancer Diagnostics Stock Is the Better Buy Now? - The Globe and Mail
bioAffinity Technologies Inc (BIAF) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
bioAffinity Technologies Inc (BIAF) Institutional Confidence - TradingKey
What's Driving bioAffinity Technologies' Recent Surge - Kavout | AI
BioAffinity Technologies and Pictor, Inc. Partner to Develop and Commercialize bioAffinity's Diagnostics for Asthma and COPD - marketscreener.com
bioAffinity Technologies, Inc. (BIAF) Stock Price, News, Quote & History - Yahoo! Finance Canada
bioAffinity and Pictor partner on diagnostics for asthma and COPD - Yahoo Finance
bioAffinity Technologies Inc (BIAF) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
BioAffinity Technologies Inc (BIAF) Fundamental & Financial Data - Stocktwits
bioAffinity Technologies and Pictor Partner to Develop High-Throughput, Cost-Effective Diagnostics for Asthma and COPD – Minichart - Minichart
bioAffinity and Pictor partner on lung inflammation diagnostics - TipRanks
bioAffinity partners with Pictor on asthma, COPD tests By Investing.com - Investing.com South Africa
bioAffinity partners with Pictor on asthma, COPD tests - Investing.com
bioAffinity Technologies partners with Pictor to develop high-throughput asthma and COPD diagnostics - TradingView
, Inc. Partner to Develop and Commercialize bioAffinity’s Diagnostics for Asthma and COPD - Business Wire
BIAF|bioAffinity Technologies Inc|Price:0.670|Chg%:+0.002 - TradingKey
Transcript : BioAffinity Technologies, Inc.Special Call - marketscreener.com
Certain Options of bioAffinity Technologies, Inc. are subject to a Lock-Up Agreement Ending on 19-JUL-2026. - marketscreener.com
Certain Warrants of bioAffinity Technologies, Inc. are subject to a Lock-Up Agreement Ending on 19-JUL-2026. - marketscreener.com
Certain Common Stock of bioAffinity Technologies, Inc. are subject to a Lock-Up Agreement Ending on 19-JUL-2026. - marketscreener.com
bioAffinity Technologies Initiates New Study for Expanding CyPath Lung Tech - Medical Product Outsourcing
bioAffinity Technologies Inc Warrant 2022- on bioAffinity Financial Disclosures & SEC Filings - TradingView
BIAF stock plunges 77% in 3 months: Should you still hold or sell? - MSN
BIAF Stock Plunges 77% in 3 Months: Should You Still Hold or Sell? - The Globe and Mail
Multidisciplinary Physician Panel to Share Real-World Benefits of bioAffinity Technologies’ Noninvasive CyPath Lung Cancer Test in Upcoming Society for Advanced Bronchoscopy Webinar - AOL.com
WallachBeth Capital Announces Closing of bioAffinity Technologies $3.2 Million Offering - AOL.com
bioAffinity reports 200% jump in lung test sales year-over-year By Investing.com - Investing.com South Africa
bioAffinity Technologies’ Quarterly CyPath® Lung Sales Double to New Record as Commercial Momentum Continues - BioSpace
bioAffinity Technologies’ CyPath Lung Test Sees Rapid Growth - TipRanks
bioAffinity Technologies Sets New Record as CyPath® Lung Sales Double with Over 200% Year-Over-Year Growth in Q2 2026 1 – Minichart - Minichart
bioAffinity reports 200% jump in lung test sales year-over-year - Investing.com
bioAffinity Technologies Q2 CyPath® Lung Sales More Than Double Year‑Over‑Year - TradingView
Bioaffinity Technologies Inc (BIAF) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.12%
자본화:
|
볼륨(24시간):